SBIR/STTR Research Award
A novel compound to selectively protect normal tissues from chemotherapy
Award amount
$147,830Program and phase
SBIR · Phase IAward year
2010Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PERSCITUS BIOSCIENCES, LLC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- PHS2010-2
- Topic code
- NCI
Research abstract
DESCRIPTION (provided by applicant): The successful treatment of human cancer depends on the ability to find treatments that kill tumor cells without impacting normal tissue significantly. An alternative approach is to selectively protect normal tissue from the toxic effects of chemotherapy while leaving the tumor cells vulnerable. Perscitus Biosciences, LLC has successfully synthesized a compound that we hypothesize will increase the protective molecule glutathione in normal tissue but not tumor tissue. Glutathione is known to protect against reactive oxygen species including those generated during the treatment of cancer with chemotherapy. In this project, we will examine the ability of the compound to selectively increase glutathione levels in normal tissue - and not tumor tissue - to protect against chemotherapy- induced toxicity. Analytic methods will be developed in conjunction with the Ohio State University Comprehensive Cancer Center Pharmacoanalytic Laboratory to allow us to measure the different metabolic steps that this compound must undergo to generate glutathione. If successful, this compound could significantly decrease much of the toxicity seen with common chemotherapy treatments of cancer. Importantly, protection of the normal tissue will allow escalation of the doses used in cancer treatment, potentially improving the ability to treat cancer effectively. PUBLIC HEALTH RELEVANCE: Over 500,000 people die from cancer in the U.S. each year. To improve the treatment of cancer, treatment regimens are needed with improved tolerability and effectiveness. The compound presented in this project has the potential to both decrease the side effects associated with cancer treatment as well as improve the anti-cancer effect.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis